Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 10/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370598 | 0.88 | SIGMAR1 (0.48) | SIGMAR1CYP1A2BCHEACHE | |
| SCHEMBL20072734 | 0.78 | HRH3 (0.33) | — | |
| SCHEMBL28402059 | 0.78 | SIGMAR1 (0.57) | SIGMAR1CYP1A2BCHEACHE | |
| SCHEMBL10324987 | 0.77 | CYP1A2 (0.54) | SIGMAR1CYP1A2BCHEACHE | |
| SCHEMBL79025 | 0.75 | — | — | |
| SCHEMBL19350960 | 0.75 | SIGMAR1 (0.64) | SIGMAR1CYP1A2METAP1 | |
| SCHEMBL22334552 | 0.75 | SIGMAR1 (0.64) | SIGMAR1CYP1A2METAP1 | |
| SCHEMBL20491433 | 0.75 | SIGMAR1 (0.64) | SIGMAR1CYP1A2METAP1 | |
| SCHEMBL932131 | 0.75 | SIGMAR1 (0.64) | SIGMAR1CYP1A2METAP1 | |
| SCHEMBL11573952 | 0.75 | SIGMAR1 (0.64) | SIGMAR1CYP1A2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180104342-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104342-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | SIGMAR1 754/4885CYP1A2 768/4885BCHE 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.